References
- KAPLAN NM: Systemic hypertension: mechanisms and diagnosis. In: Heart Disease. Braunwald E (Ed.). WI3 Saun-ders (1992).
- World Health Organization Bulletin (1993) 71(5):503–517.
- CHRISTEN Y, WAEBER B, NUSSBERGER J, ET AL.: Oral administration of DuP 753, a specific angiotensin II receptor antagonist to normal male volunteers. Inhibi-tion of pressor response to exogenous anglotensin I and U. Circulation (1991) 83:1333–1342.
- GOLDBERG A: Efficacy and safety of losartan. Can. J. Cardiol. (1995) 11(Suppl. E). In Press.
- DAHLOF B, KELLER SE, MAKRIS L: Efficacy and tolerabil-ity of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am. J. Hyper-tens. (1995) 8:578–583.
- GRADMAN All, ARCURI KE, GOLDBERG AL, ET AL.: A randomized, placebo-controlled double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hyper-tension. Hypertens. (1995) 25:1345–1350.
- NELSON EB, MERRILL DM, SWEET CS, ETAL.: Efficacy and safety of oral MK-954 (DuP 753), an angiotensin recep-tor antagonist, in essential hypertension. J. Hypertens. (1991) 9\(Suppl. 6):S468–S469–
- GOLDBERG AL, DUNLAY MC, SWEET CS: Safety and tol-erability of losartan potassium, an angiotensin receptor antagonist, compared with hydrochlorothiazicle, atenolol, felodipine ER and angiotensin-converting en-zyme inhibitors for the treatment of systemic hyper-tension. Am. J. Cardiol. (1995) 75:793–795.
- SACHINIDID A, KO Y, WEISSER P, ETAL.: EXP 3174, a metabolite of losartan (MK-954, DuP 753) is more po-tent than losartan in blocking the angiotensin 11 in-duced responses in vascular smooth muscle cells. J. Hypertens. (1993) 11:155–162.
- LO M-W, LU H, FARRELL DM, ETAL.: Pharmacokinetics of Intravenous EXP-3174, an active metabolite of losartan In man. Pharm. Res. (1992) 9:S308.
- SWEET CS, BRADSTREET DC, BERMAN RS, ETAL.: Pharma-codynarnic activity of intravenous E-3174, an angioten-sin II antagonist, in patients with essential hypertension. Am. J. Hypertens. (1994) 7:1035–1040.
- SRAMEK JJ, CUTLER NR, SEIFERT RD, ETAL.: Compliance In hypertension: Daily vs. twice daily. Am. J. Hypertens. (1993) 6:1063.
- HUCKLE WR, EARP HS: Regulation of cell proliferationand growth by angiotensin U. Prog. Growth Factor Res. (1994) 5:177–194.
- HUSAIN A: The chymase angiotensin system in humans.Hypertens. (1993) 11:1155–1159.